Abstract
Erectile dysfunction is a common disease of the male reproductive system, which seriously affects the life quality of patients and their partners. At present, erectile dysfunction is considered as a social-psychological-physiological disease with complex etiology and various treatment methods. Oral PDE5I is the first-line treatment for erectile dysfunction with the advantages of high safety, good effect and non-invasiveness. But intracavernosal injection, hormonal replacement therapy, vacuum erection device, penile prosthesis implantation can also be alternative treatments for patients have organic erectile dysfunction or tolerance to PDE5I. With the rapid development of technologies, some new methods, such as low-intensity extracorporeal shock wave and stem cell injection therapy can even repair the organic damage of the corpora cavernosa. These are important directions for the treatment of male erectile dysfunction in the future. In this mini-review, we will introduce these therapies in detail.
Introduction
Erectile dysfunction (ED) is a significant health concern affecting the male reproductive system, with profound impacts on the quality of life for both patients and their partners. Currently understood as a complex social-psychological-physiological condition, ED affects over 150 million men globally. Its prevalence is strongly correlated with age, impacting more than 70% of men over the age of 70. While traditional treatments focus on symptom management, the field is shifting toward regenerative approaches that aim to repair underlying organic damage rather than just temporarily alleviating symptoms.
Current Therapeutic Landscape
The management of ED typically follows a tiered approach based on invasiveness and patient response.
First-line treatment primarily involves oral Phosphodiesterase 5 inhibitors (PDE5Is), such as sildenafil (Viagra) and the newer avanafil, which boasts a rapid onset of action within 15 minutes. These drugs work by blocking the decomposition of cGMP, thereby enhancing the NO/cGMP signaling pathway to relax smooth muscle and increase blood flow to the penis. Despite their high safety profile and efficacy, approximately 30% of patients eventually develop a tolerance or fail to respond to these medications.
For those unresponsive to oral medications, second-line options include Intracavernosal Injections (ICI) and Vacuum Erection Devices (VED). ICI involves the direct delivery of vasoactive drugs like papaverine or prostaglandin E1 into the corpora cavernosa to induce an erection. VEDs utilize negative pressure to mechanically draw blood into the penis. When these methods fail, third-line surgical intervention via Penile Prosthesis Implantation (PPI) provides permanent structural support through inflatable cylinders.
Emerging Regenerative Therapies
The most exciting developments in ED management involve therapies that seek to restore natural function rather than just providing temporary mechanical or chemical assistance. These regenerative methods aim to reverse organic damage to the penile tissue.
- Low-intensity extracorporeal shock wave (Li-ESW): This therapy uses low-energy sound waves to stimulate the expression of vascular growth factors, such as VEGF, inducing neovascularization (new blood vessel growth). Clinical data suggests significant promise; one pilot study showed a 75% improvement rate in patients with vascular ED. Furthermore, Li-ESW has demonstrated the ability to reverse PDE5I tolerance in over 50% of previously unresponsive patients.
- Stem Cell Injection: This frontier utilizes mesenchymal, adipose, or urine-derived stem cells. Rather than simply replacing tissue, these cells operate through paracrine action, secreting exosomes and cytokines that promote angiogenesis and inhibit cell death in the corpora cavernosa. In a phase 1 clinical trial, 73% of post-prostatectomy patients who were previously unresponsive to standard drugs recovered erectile function within three months of a single injection of autologous adipose-derived regenerative cells.
Conclusion and Future Directions
The future of ED treatment lies in the transition from symptomatic management to curative regenerative medicine. While current results from Li-ESW and stem cell therapies are encouraging, many findings are still based on animal models or small-scale pilot studies. There is an urgent need for large-scale, randomized, placebo-controlled clinical trials to establish long-term safety and efficacy. As technologies like gene-edited stem cells and 3D-printed hydrogel scaffolds advance, the goal of fully restoring organic erectile function becomes increasingly attainable.
Summary updated